Cleveland Clinic researchers have identified three proteins in the seminal plasma of men with varicocele that can help serve as biomarkers in the diagnosis of fertility issues.
A recent study from Cleveland Clinic shows certain genomic biomarkers appear to be as important as standard clinical factors in identifying which patients are candidates for surveillance or treatment at diagnosis.
Current biomarkers used in giant cell arteritis (GCA) and Takayasu arteritis (TAK) are insufficiently specific for assessing disease activity. This study assessed whether S100 proteins were associated with disease activity in GCA and TAK.
Translational work combining human plasma studies and previous mouse model data will enable identification of new, precise biomarkers and potential treatment pathways that may help pinpoint and treat RA and PsA patients at increased risk of CV disease.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Study finds noninvasive scores can help identify cirrhosis in patients who are at high risk due to having nonalcoholic fatty liver disease and type 2 diabetes.
From heart benefits of diabetes drugs to leadless pacing to expanding populations for TAVR, 2016 was a dynamic year in cardiovascular care. Cleveland Clinic experts reflect on a dozen key developments.
Objective disease markers may be needed more desperately in adolescent suicidal ideation than in any other condition. A psychiatrist explains how her new study might identify such biomarkers.
Cleveland Clinic researchers have found evidence that the circulating astrocytic protein S100B might be useful as a biomarker for blood-brain barrier breakdown triggered by childhood trauma and abuse. If further validated, a serum test for S100B could help clinicians assess the severity of emotional injury and the need for intervention.
Alzheimer disease, Parkinson disease, normal aging and neuroinflammation are priority focus areas of the biobank, which aim to promote identification of novel biomarkers. The facility will benefit from Cleveland Clinic’s large, diverse patient population and neuroinflammation research expertise.